Insider Purchases: Inside the Buy
Tag: Short Squeeze
🧬 Annexon (ANNX): Insiders Buy Millions While Wall Street Bets Against a Breakthrough
Annexon Biosciences is one of the more intriguing biotech setups of 2026. Directors are buying millions of dollars of stock, institutions own virtually the entire float, short interest is elevated, and multiple clinical and regulatory catalysts loom before year-end. High risk? Absolutely. High potential reward? Possibly.
🚀 Upstart Stock: Founder Buys $5M as AI Lending Underdog Faces Short-Squeeze Setup
Upstart stock is back in Wall Street’s drama zone: insider buying, massive short interest, AI lending growth, cash-flow concerns, and a possible bank-charter catalyst. High risk? Absolutely. Boring? Not even close.
CORT Stock 2026: FDA Rejection, Insider Buying… and a Brewing Short Squeeze?
Corcept Therapeutics just got hit with an FDA rejection—but insiders are buying millions and short interest is surging. With a profitable base business and major 2026 catalysts ahead, CORT may be one of the most explosive “binary bets” in biotech today.
MTN Stock Analysis 2026: Why Rob Katz’s $5M Buy Signals a Peak Opportunity in Vail Resorts
Vail Resorts (MTN) just endured one of the worst snowfall seasons in decades—yet insiders are buying millions in stock. With a powerful Epic Pass model, heavy institutional ownership, and rising short interest, this mountain stock may be setting up for a contrarian move.
HOG Stock Analysis 2026: Harley-Davidson’s High-Stakes Turnaround — Value Trap or Coiled Spring?
Harley-Davidson stock is down more than 75% from its historic highs, but insiders are buying, institutions own over 100% of the float, and short sellers are circling. Is HOG a value trap… or a contrarian opportunity ready to roar?
FOUR Stock Analysis 2026: Is Shift4 a Payments Powerhouse or a Falling Knife?
Shift4 (FOUR) is a full-blown battleground stock. Founder buying, 35% short interest, heavy institutional ownership, and a forward P/E near 7. Rocket fuel — or engine trouble?
AbCellera (ABCL) Stock Analysis: 7 Triggers for a Biotech Short Squeeze or Long-Term Multibagger?
Down 95%, heavily shorted, yet sitting on $700M in liquidity and insider conviction — AbCellera (ABCL) may be biotech’s ultimate asymmetric bet.
Ryan Cohen Buys More GameStop; Time to Play — or Make This Story Short?
Ryan Cohen doubles down on GameStop. Shorts stay crowded. Analysts stay bearish. But profits, cash, and conviction are back. Is GME still a meme — or a mispriced turnaround? 🎯🎮
Insiders Purchase Shares of Goosehead Insurance — Should You Buy, Duck, or Just Take a Gander?
Insiders are loading up on Goosehead Insurance shares — and institutions can’t get enough. With strong growth but real risks, is this goose ready to fly… or cooked? Here’s the fun, smart breakdown. 🪿📈🔥
Insiders Pile Into Opendoor (OPEN) as New CEO Kasra Nejatian Bets on an ‘AI-First, Software-First’ Future — Should You Join the Cult Stock Rally?
Insiders are buying, retail traders are chanting, and Opendoor has a new AI-first CEO. From near-delisting to cult stock darling — is OPEN worth the hype?